Athanor Capital, LP Reata Pharmaceuticals Inc Transaction History

Athanor Capital, LP

  • $24.6 Million
  • Q4 2022

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$93.53 - $163.34 $195,384 - $341,217
-2,089 Closed
0 $0
Q2 2020

Aug 13, 2020
BUY
$126.3 - $176.56 $263,840 - $368,833
2,089 New
2,089 $326,000
Q1 2020

May 14, 2020
SELL
$124.16 - $247.74 $509,056 - $1.02 Million
-4,100 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$74.57 - $217.92 $85,009 - $248,428
-1,140 Reduced 21.76%
4,100 $838,000
Q3 2019

Nov 14, 2019
BUY
$71.26 - $95.75 $188,126 - $252,780
2,640 Added 101.54%
5,240 $421,000
Q2 2019

Aug 13, 2019
BUY
$77.72 - $94.35 $202,072 - $245,309
2,600 New
2,600 $245,000

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Athanor Capital, LP Portfolio

Follow Athanor Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Athanor Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email